Curie Capital is a Life Sciences focused venture capital firm specialized in investing in early-stage companies, supporting talented teams with exciting new medical products.

Curie Capital

Curie Capital BV

Looking to connect with us? Coming week our associate Thom Frielink will be present at the Global Investor Forum (March 27) and Innovation for Health (March 28).

❕Today, Citryll is happy to announce the appointment of Maarten Kraan as our new Chief Medical Officer. 

We are very excited to have Maarten on board! As we begin a new chapter at Citryll, his experience will be invaluable in advancing CIT-013, our lead antibody, into Phase 2a proof-of-concept studies in rheumatoid arthritis and hidradenitis suppurativa.

➡ Take a look at our press release for the full details of this announcement: https://lnkd.in/dNjVwfsq

Curie Capital BV is proud to announce its latest investment: we are honored to continue our commitment to the newly named Flindr (formerly Immagene), as part of their €20 million Series A financing to advance first-in-class small molecule inhibitors. This round is led by V-Bio Ventures with an international syndicate which includes Johnson & Johnson Innovation JJDC Inc, Qbic Fund | Venture Capital, PMV, as well as seed investors Oncode Oncology Bridge Fund, Swanbridge Capital and Brabantse Ontwikkelings Maatschappij (BOM). Flindr (formerly Immagene) discovers and develops precision oncology therapeutics with the potential to eradicate tumors in specific patient populations. Their lead asset is a first-in-class small molecule inhibitor of the cancer driver RNF31. 

For more information, please see https://lnkd.in/eQ64JYH8

Curie Capital has exciting news from its clinical stage portfolio company #Citryll, developing CIT-013 to treat immune-mediated inflammatory diseases (IMIDs):

We welcome Eduardo Bravo (CEO) and Tim Schenk (CBO), who are joining the great team of Citryll!

https://lnkd.in/exsD57X8

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jul 18, 2024 8:00 AM	8cf6440a
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 4, 2024 10:53 AM	e5a1635e
crunchbase profile	general
li profile	general	Jul 18, 2024 8:00 AM	0609c5c4
translate crunchbase fundingrounds	general
peers	general	Jul 18, 2024 8:00 AM	47431d02
news basic	general	Jul 18, 2024 8:00 AM	f6c5639c
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

CURI

NL:CURIECAPITAL

Curie Capital